Table 1 Comparison of the 60 patients that were excluded from the study with the 141 that remained (percentages calculated for the two groups)
From: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
60 excluded | 141 remained | Chi-square, significance | |
|---|---|---|---|
Age (years) | 4.08, p = 0.04 | ||
≤ 73 | 38% | 54% | |
> 73 | 62% | 46% | |
Gender | n.s. | ||
Male | 85% | 82% | |
Female | 15% | 18% | |
Tumor size | n.s. | ||
≤ 3 cm | 50% | 48% | |
> 3 cm | 50% | 52% | |
Tumor grade | n.s. | ||
2 | 20% | 14% | |
3 | 80% | 86% | |
LVI* | n.s. | ||
No | 77% | 68% | |
Suspected | 20% | 23% | |
Yes | 3% | 9% | |
p21 | 26.6, p < 0.001 | ||
Abnormal | 48% | 14% | |
Normal | 52% | 86% | |
p53 | n.s. | ||
Abnormal | 82% | 74% | |
Normal | 18% | 26% | |
pRb | n.s. | ||
Abnormal | 88% | 84% | |
normal | 12% | 16% | |
p16 | n.s. | ||
Abnormal | 58% | 58% | |
Normal | 42% | 42% | |
Recurrence | n.s. | ||
No | 78% | 82% | |
Yes | 22% | 18% | |
Progression | n.s. | ||
No | 40% | 38% | |
Yes | 60% | 62% |